Waters (WAT) Q1 2026 earnings review
Core Business Accelerates While BD Acquisition Crushes Initial Targets
Waters delivered an exceptional Q1, silencing doubts around its massive BD Biosciences and Diagnostic Solutions (BDS) acquisition. Organic constant currency revenue growth accelerated to 11% (from 6% last quarter), driven by high-single-digit instrument and mid-teens chemistry growth in the legacy Analytical Sciences Division. The newly acquired BDS segment generated $520M, easily beating the conservative $480M guidance management laid out in February. While GAAP EPS swung to a $0.87 loss due to $239M in purchase accounting and inventory step-ups, Adjusted EPS surged 20% to $2.70. Management raised full-year organic growth and EPS guidance, though Q2 guidance points to a near-term deceleration in earnings growth as interest expenses temporarily outweigh early synergy capture.
🐂 Bull Case
The BDS segment generated $520M in its first partial quarter, beating expectations by $40M. Management cited immediate traction in commercial execution and cross-divisional synergy realization.
Organic revenue grew 11% CC, significantly outperforming the 7-9% Q1 guidance. The core Analytical Sciences Division's 14% reported growth confirms the multi-year instrument replacement cycle remains highly robust.
🐻 Bear Case
Interest expense quadrupled YoY from $10M to $42M following $3.5B in debt issuances. This debt load will restrict near-term EPS growth leverage until cost synergies fully materialize.
Adjusted operating margin compressed from 25.5% in Q1 25 to 23.6% in Q1 26, confirming that the newly acquired BD assets carry a structurally lower margin profile that will take time to elevate.
⚖️ Verdict: 🟢
Bullish. The core legacy business is accelerating, and the largest risk—underperformance of the acquired BD assets—was dismantled by a $40M revenue beat in the first 50 days of ownership. Near-term margin compression was expected and is overshadowed by the top-line momentum.
Key Themes
Acquired BDS Segment Shrugs Off Q4 Weakness
During the Q4 25 call, management warned that the BD assets were underperforming due to China diagnostics headwinds and flu season dynamics, guiding a cautious $480M for Q1. Instead, BDS delivered $520M. This $40M beat proves the 'Waters playbook' of execution discipline is already reversing the acquired segment's slide, prompting a raise in the FY26 BDS revenue expectation to $3.035B.
Analytical Sciences Engine Roars
The legacy Waters business, now dubbed the Analytical Sciences Division (ASD), accelerated with 14% reported growth to $607M. This was driven by high-single-digit instrument growth (validating the ongoing replacement cycle narrative) and mid-teens chemistry growth, proving that the core portfolio remains highly competitive independent of M&A.
Product Innovation Fuels Momentum
Management explicitly credited the success of new product launches as a primary catalyst for the organic revenue beat. Momentum in the instrument replacement cycle relies heavily on adoption of recent innovations like the Alliance iS HPLC and the Xevo mass spec platforms, which continue to drive hardware volume and subsequent high-margin chemistry pull-through.
Q2 EPS Growth Deceleration Contradicts Full-Year Excitement
Despite raising the full-year Adjusted EPS outlook to double-digit growth (10-11%), Q2 26 Adjusted EPS guidance of $2.95 to $3.05 implies flat to 3.4% YoY growth. This sharp deceleration from Q1's 20% growth indicates that the massive interest expense and share count dilution from the BD acquisition are temporarily overpowering operating leverage.
Materials Sciences (TA) Remains the Laggard
The Materials Sciences Division (formerly TA Instruments) reported $79M in revenue, up just 6% YoY. While this is stable compared to previous quarters, it significantly lags the 14% growth of the ASD segment, indicating that macroeconomic sensitivities in industrial and polymer testing remain a localized headwind.
Macro: Ballooning Interest Expense Hits the P&L
To fund the BD acquisition, Waters issued $3.53B in new debt, pushing total notes payable and debt to $5.2B. Consequently, Q1 net interest expense spiked to $42M (up from $10M in 25Q1). In a higher-for-longer interest rate environment, this permanently elevated debt service cost creates a higher hurdle for bottom-line beats.
Other KPIs
Reversing. Down from 25.5% in 25Q1. This 190 basis point compression is a direct result of integrating the structurally lower-margin BD business. Management's long-term thesis relies on pulling this margin up toward the legacy Waters baseline (historically ~30%+), making this a critical metric to watch over the next 12-18 months.
Reversing from a $121M profit a year ago. The loss is purely accounting-driven, burdened by $140M in purchased intangible amortization and a $99M inventory fair value step-up related to the BDS acquisition. Investors should focus strictly on Adjusted figures, but the sheer size of the GAAP loss highlights the premium paid for the assets.
Accelerating dramatically on a reported basis due to the BDS integration. However, the organic CC growth of 11% suggests broad-based global strength in the legacy portfolio, defying earlier fears of deep weakness in the Chinese market.
Guidance
Accelerating. Management raised the floor from the initial 5.5%-7.0% guidance provided in February. This upgrade, following an 11% print in Q1, signals deep confidence that the instrument replacement cycle has staying power through the back half of the year.
Accelerating vs initial expectations. Raised from the initial $3.0B target given at the time of the deal close. This incorporates $35M of expected revenue synergies for the remainder of the year, up from previous internal conservative baselines.
Accelerating. Raised from the prior $14.30-$14.50 range. The new midpoint ($14.50) implies roughly 10.5% YoY growth over FY25's $13.13. This shows that despite heavy interest expenses, the top-line beat is flowing through to the bottom line.
Decelerating. The Q2 midpoint of $3.00 implies just a 1.7% YoY increase over 25Q2 ($2.95). Management will have to explain why Q1 delivered 20% growth while Q2 halts to a crawl, likely pointing to the full-quarter weight of the $3.5B debt load and the dilution of the lower-margin BDS business before synergies ramp.
Key Questions
Bridge from Q1 to Q2 EPS Growth
Adjusted EPS grew 20% in Q1, but Q2 guidance implies roughly flat to 3% growth. Can you bridge the margin and interest expense dynamics causing this sharp sequential deceleration in earnings leverage?
BDS Baseline Margin Progression
You achieved a $40M revenue beat on the BDS asset out of the gate. Given the adjusted operating margin compressed to 23.6% this quarter, what is the exact timeline to see the BDS margin profile inflect upward toward legacy Waters levels?
Instrument Cycle Longevity
With organic CC growth accelerating to 11% and instruments leading the charge, how much of this is clearing out aged backlog versus genuine greenfield expansion? Do you expect the mid-teens chemistry growth to cool as instrument placements normalize?